| Name | Title | Contact Details |
|---|
Mirada provide medical imaging and software solutions for AI autocontouring. We help healthcare professionals to accelerate cancer care.
Exceptional trading, investment and information solutions for the world`s financial community. New technology, new regulation, new challenges: making money in today`s financial markets is all about staying ahead of the curve. Having the capability to spot new trends and act fast turns change into opportunity. That`s why 85% of the world`s premier financial institutions trust Fidessa to provide them with their multi-asset trading and investment infrastructure, their market data and analysis, and their decision making and workflow technology. It`s also why $20 trillion worth of transactions flow across our global network each year. Because we`re the market leader, we can also offer unique access to the world`s largest and most valuable trading community of buy-side and sell-side professionals, from global institutions and investment banks to boutique brokers and niche hedge funds. Fidessa is a global business with scale, resilience, ambition and expertise. We`ve delivered around 25% compound growth since our stock market listing in 1997 and we`re recognised as the thought leader in our space. We set the benchmark with our unrivalled set of mission-critical products and services and, uniquely, serve both the buy-side and sell-side communities. Ongoing investment in our leading-edge, integrated solutions ensures Fidessa remains the industry`s number one choice.
NOVAtime Technology is a Diamond Bar, CA-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Forter is the Trust Platform for digital commerce. With Forter, enterprises generate more revenue and reduce losses to fraud and abuse by making accurate and real-time decisions about every digital interaction. Forter was founded on the insight that it`s not about what is being purchased, nor where, but who is behind the interaction. As a result, Forter continues to expand its global customer network— processing more than $250 billion in gross merchandise value per year. As the company grows, its customers benefit further; a fraudster detected by one customer is instantly recognizable to all Forter customers. Only automation can facilitate the speed, scale, and accuracy needed to approve more transactions, block more fraud attempts, and deliver better customer experiences. Forter is entrusted by digital commerce leaders across industries, including Nordstrom, Sephora, Instacart, Adobe, Priceline, and more. These businesses are committed to ensuring that everyone who visits their sites gets the experience they deserve.